Bristol-Myers commits up to $1.2bn in CytomX deal
This article was originally published in Scrip
CytomX Therapeutics will get a $50m upfront payment from Bristol-Myers Squibb and is eligible to receive up to $1.2bn in milestone fees plus research funding and royalties under an agreement to discover, develop and commercialize novel immunotherapies.
You may also be interested in...
Bristol-Myers Squibb expanded its collaboration with CytomX for $200m up front and up to $3.6bn in milestone fees. Also, Takeda spun out eight non-core molecules into a new joint venture and X-Chem executed two deals with Japanese partners, among other recent deals.
Antibody-drug conjugates have taken a back seat to cancer immunotherapy as the hot modality in oncology of late, but AbbVie Inc. and CytomX Therapeutics Inc. unveiled a partnership on April 20 to develop an ADC in a deal that CytomX cites as further validation of its Probody technology platform.
The drug showed favorable but not significant trends across secondary endpoints, and greater efficacy in slower-progressing patients and those treated earlier in the disease, in a small subpopulation.